Fracture prevention in postmenopausal women

Overview

Abstract | Cite as | Substantive changes

Abstract

INTRODUCTION: The lifetime risk of fracture in white women is 20% for the spine, 15% for the wrist, and 18% for the hip, with an exponential increase in risk beyond the age of 50 years. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of bisphosphonates to prevent fractures in postmenopausal women? What are the effects of pharmacological treatments other than bisphosphonates to prevent fractures in postmenopausal women? What are the effects of non-pharmacological treatments to prevent fractures in postmenopausal women? We searched: Medline, Embase, The Cochrane Library, and other important databases up to September 2010 (Clinical Evidence reviews are updated periodically, please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 71 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: alendronate, calcium, calcium plus vitamin D, clodronate, denosumab, etidronate, exercise, hip protectors, hormone replacement therapy, ibandronate, multifactorial non-pharmacological interventions, pamidronate, parathyroid hormone, raloxifene, risedronate, strontium ranelate, vitamin D, vitamin D analogues, and zoledronate.dfsg

Cite as

Vestergaard P, Mosekilde L and Langdahl B. Fracture prevention in postmenopausal women. Clinical Evidence 2011; 05:1109.

Top

Substantive changes

Alendronate New evidence added to harms of bisphosphonates.[14][17][12][19][20][21] Categorisation unchanged (Beneficial) as benefits continue to outweigh adverse effects.

Risedronate New evidence added to harms of bisphosphonates.[14][17][12][19][20][21] Categorisation unchanged (Beneficial) as benefits continue to outweigh adverse effects

Ibandronate New evidence added to harms of bisphosphonates.[14][17][12][19][20][21] Categorisation unchanged (Likely to be beneficial) as benefits continue to outweigh adverse effects

Clodronate New evidence added to harms of bisphosphonates.[14][17][12][19][20][21] Categorisation unchanged (Likely to be beneficial) as benefits continue to outweigh adverse effects.

Pamidronate Evidence reassessed. Categorised as Unknown effectiveness (as RCT evidence found was not of sufficient quality to assess its effects).

Denosumab New option added.[41][42] Categorised as Beneficial.

Calcium alone New evidence added to harms section.[75] Categorisation changed (from Unlikely to be beneficial to Likely to be ineffective or harmful).

Vitamin D alone New evidence added.[79][80] Categorisation unchanged (Unlikely to be beneficial).

Calcium plus vitamin D New evidence added.[79] Categorisation unchanged (Likely to be beneficial).

Exercise New evidence added.[88] Categorisation unchanged (Unknown effectiveness), as there remains insufficient evidence to judge the effects of this intervention in postmenopausal women.

Hip protectors New evidence added.[97] Categorisation unchanged (Likely to be beneficial).

Latest citations

Comparative Effectiveness of Pharmacologic Treatments to Prevent Fractures: An Updated Systematic Review. ( 10 October 2014 )

Effect of 12 months of whole-body vibration therapy on bone density and structure in postmenopausal women: a randomized trial. ( 18 September 2014 )